Drugs influencing the nervous system. Parasympathomimetics. Choline alfoscerate
Alphacholine is a drug that belongs to the group of central cholinomimetics with a predominant effect on the central nervous system (CNS). Choline alfoscerate as a carrier of choline and a precursor agent of phosphatidylcholine has the potential to prevent and correct biochemical damage, which is particularly important among the pathogenic factors of psychoorganic involutional syndrome, i.e. can affect reduced cholinergic tone and altered phospholipid composition of membranes of ganglion cells. The drug contains 40.5% of metabolically protected choline. Metabolic protection ensures the release of choline in the brain. Alphacholine has a positive effect on memory functions and cognitive abilities, as well as on indicators of emotional state and behavior, the deterioration of which was caused by the development of an involutional brain pathology.
Acute period of severe traumatic brain injury with predominantly stem level of damage (disturbance of consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage).
Degenerative-involutional cerebral psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, i.e. primary and secondary mental disorders in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased ability to concentrate; changes in the emotional sphere and the sphere of behavior: emotional instability, irritability, indifference to the environment; pseudomelancholia in the elderly.
In acute conditions, Alphacholine should be administered intramuscularly or intravenously (slowly), 1 g (1 ampoule) per day for 15 to 20 days. Then, after the patient's condition becomes stable, switch to the dosage form of the drug in capsules.